VEGFA and diabetic macular edema: Currently, 4.3 million people worldwide are affected by blindness, but the total number could increase to 61 million by 2050.46 Amongst the leading causes of blindness, age-related macular degeneration (AMD) alone is affecting 67 million patients in Europe, and due to an aging population, is expected to impair 77 million by 2050, displaying similar trends globally.47–49 Intravitreal injections of anti-VEGF (vascular endothelial growth factor) treatments are effective in reducing neovascularization in the disease progress of AMD, or diabetic macular edema (DME).